Related references
Note: Only part of the references are listed.Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities
Grace Lu-Yao et al.
EUROPEAN UROLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
Aino Siltari et al.
PLOS ONE (2020)
Cardiovascular Complications of Prostate Cancer Treatment
Michal Wilk et al.
FRONTIERS IN PHARMACOLOGY (2020)
European cancer mortality predictions for the year 2019 with focus on breast cancer
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2019)
Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events A Systematic Review and Meta-analysis
Shaojie Chen et al.
JAMA NETWORK OPEN (2019)
Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade
Michael V. Fiandalo et al.
Oncotarget (2018)
Prevention of chemo-induced cardiotoxicity with ACE inhibitors and angiotensin receptor blockers
Purva Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Angiotensin 1-7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer
Kamila Dominska et al.
SCIENTIFIC REPORTS (2018)
Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen
Monika Dlugosz-Danecka et al.
CHEMOTHERAPY (2018)
Angiotensin II receptor blockers induce autophagy in prostate cancer cells
Yunseo Woo et al.
ONCOLOGY LETTERS (2017)
The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada
Margot K. Davis et al.
JOURNAL OF ONCOLOGY (2015)
Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer
Mara M. Epstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines
Sebastian Szmit et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
Sebastian Szmit et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Engagement of Renin-Angiotensin System in Prostate Cancer
H. Uemura et al.
CURRENT CANCER DRUG TARGETS (2011)
Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Massimo Perachino et al.
BJU INTERNATIONAL (2010)
ACE inhibitor use was associated with lower serum dehydroepiandrosterone concentrations in older men
T. Kwok et al.
CLINICA CHIMICA ACTA (2010)
Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden
Mieke Van Hemelrijck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The renin-angiotensin system and cancer: old dog, new tricks
Amee J. George et al.
NATURE REVIEWS CANCER (2010)
Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer
Gunnar Ronquist et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2009)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma
Hwyda A. Arafat et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2007)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance
M DeLong et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2005)
Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
A O'Donnell et al.
BRITISH JOURNAL OF CANCER (2004)
Renin-angiotensin system and atherothrombotic disease - From genes to treatment
DS Jacoby et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
B Dahlöf et al.
LANCET (2002)
Share Paper
